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bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid
oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and
therapeutic index, pharmacokinetic properties, data related to the possibility of
excipient interactions and reported BE/bioavailability (BA) studies were also taken
into consideration in order to ascertain whether a biowaiver can be recommended.
According to the Biopharmaceutics Classification System (BCS) and considering tablet
strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries
also 800 mg tablets are available which fall just within BCS Class IV. Aciclovir seems not
to be critical with respect to a risk for bioinequivalence, as no examples of bioinequi-
valence have been identified. It has a wide therapeutic index and is not used for critical
indications. Hence, if: (a) the test product contains only excipients present in aciclovir
solid oral IR drug products approved in ICH or associated countries, for instance as
presented in this article; and (b) the comparator and the test product both are very
rapidly dissolving, a biowaiver for IR aciclovir solid oral drug products is considered
justified for all tablet strengths.  2008 Wiley-Liss, Inc. and the American Pharmacists
Association J Pharm Sci 97:5061–5073, 2008Keywords: absorption; aciclovir; bioequivalence; biopharmaceutics classification
system (BCS); permeability; solubility; regulatory sciencereflects the scientific opinion of the authors and
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5062 ARNAL ET AL.INTRODUCTION
A biowaiver monograph of aciclovir based on
literature data is presented. The risks of basing a
BE assessment on in vitro rather than in vivo
study results for the approval of new IR solid oral
dosage forms containing aciclovir (‘‘biowaiving’’),
including both reformulated products and new
multisource products, are evaluated under con-
sideration of its biopharmaceutical and clinical
properties. This evaluation refers to drug pro-
ducts containing aciclovir as the only active
pharmaceutical ingredient (API) and not to
combination drug products.
The purpose and scope of this series of mono-
graphs have been previously discussed.1
Summarized in few words, the aim is to evaluate
all pertinent data available from literature
sources for a given API to assess the risks
associated with a biowaiver. For these purposes,
risk is defined as the probability of an incorrect
biowaiver decision as well as the consequences
of the decision in terms of public health and
individual patient risks. On the basis of these
considerations, a recommendation can be made
as to whether a biowaiver is advisable or not. This
systematic approach to recommend or advise
against a biowaiver decisions is referred to in
the recently published World Health Organiza-
tion (WHO) Guideline.2 It is to be understood
that these monographs do not simply apply the
WHO,2 FDA,3 and EMEA Guidances,4 but also
aim to serve as a critical validation of these
regulatory documents. Biowaiver monographs
have already been published for acetaminophen
(INN: paracetamol),5 acetazolamide,6 amitripty-
line,7 atenolol,1 chloroquine,8 cimetidine,9 etham-
butol,10 ibuprofen,11 isoniazid,12 prednisolone,13
prednisone,14 pyranisamide,15 propranolol,1 rani-
tidine,16 and verapamil.1 They are also available
on-line at www.fip.org/bcs.EXPERIMENTAL
Literature data was assessed from PubMed17 and
Micromedex18 databases. Keywords used for
searching, in various combinations were: aciclo-
vir, acyclovir, solubility, permeability, dissolu-
tion. Information was also obtained from
regulatory documents published by the EMEA,4
the FDA,3 and the WHO.2,19 The USP20and the
European Pharmacopoeia21 were also consulted
when necessary.JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200GENERAL CHARACTERISTICS
Name
The INN and WHO chemical name for aciclovir is
2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-
6H-purin-6-one, or 9-[(2-hydroxyethoxy)methyl]-
guanine.20,22 Other names are: acyclovir, acyclo-
guanosine and ACV.23 Its molecular formula
is C8H11N5O3, and its molecular weight is 225.21
g/mol. Its CAS number is 59277-89-3.20,22Therapeutic Indications, Therapeutic
Index and Toxicity
Aciclovir is used orally for the treatment and
prophylaxis of initial and recurrent episodes
of genital and labial herpes and for the acute
treatment of herpes zoster for the treatment of
varicella (chickenpox) in immunocompetent indi-
viduals.24,25 Its defined daily dose, either orally or
parenterally, is 4 g.26 Oral administration up to
doses of 4800 mg/day is usually well tolerated
although high-dose treatment with oral aciclovir
for herpes zoster results can cause more side
effects than low-dose treatments.27 Several
patients have ingested up to 100 capsules,
corresponding to 20 g of aciclovir, with no
apparent adverse effects,28 probably due to the
limited solubility and absorption characteristics.
Neurotoxicity may be seen with high doses in
patients with compromised renal function.28–30
Neurotoxicity can include coma, confusion,8 DOI 10.1002/jps
BIOWAIVER MONOGRAPH FOR ACICLOVIR 5063delirium, encephalopathy, hallucinations, pares-
thesias, psychosis, seizures, or tremor. Neurologic
adverse reactions usually occur within 1–2 days of
achieving the maximum aciclovir concentration
and may not be directly correlated with the
aciclovir serum concentrations at the time the
toxic effects appear. The threshold for neurotoxi-
city was reported to be 4.5 mg/mL, whereas the
normal peak range is 0.4–2 mg/mL.28 Diarrhea,
nausea and vomiting, and elevated serum crea-
tinine levels may be observed in conjunction with
plasma levels over 20 mcg/mL, but recede when
the dose is reduced.28
Serious neurological and/or psychiatric adverse
effects been reported in a few patients adminis-
tered bolus injections of high doses intravenous
aciclovir.27,28,30 Aciclovir has low solubility in
urine and aciclovir crystals may precipitate in the
renal tubules if the solubility is exceeded in the
intratubular fluid, resulting in renal dysfunction,
renal failure or anuria,24,28 but this crystalluria is
most likely to occur only during administration of
large, parenteral doses. All these latter adverse
drug reactions are not associated with the oral
administration and hence are not relevant for this
monograph.Table 1. Solubility Data at 378C and the






200 mgc 400 mg 800 mgd
1.2 >3.5 <57 <114 <229
4.5 2.6 77 154 308e
5.8 2.3 87 174 348e
6.8 2.4 83 167 333e
7.4 2.5 80 160 320e
aData read from the plot published by Shojaei et al.48
bCritical limit: <250 mL.2–4
cStrength of WHO Essential Medicines List.19
dHighest strength on some EU markets and the USA
market.
eExceeds critical limit.PHYSCOCHEMICAL PROPERTIES
Salts, Esters, Polymorphs, Hydrates
Aciclovir is commonly used as the free acid form in
solid oral dosage forms, whereas the sodium salt is
used in parenteral dosage forms.22,23 Valaciclovir,
the L-valyl ester of aciclovir, has been used orally to
increase its BA.31–36 Several dipeptide ester pro-
drugs are being tested to assess their usefulness in
therapeutics,37,38 as well as some bile acid conjugate
prodrugs39 and a phospholipid prodrug.40 The scope
of this monograph is restricted to drug products
containing aciclovir as the free acid.
Aciclovir is normally present in a hydrated form
consisting of three aciclovir molecules to two
molecules of water,41 corresponding to a theore-
tical water content of about 5%, but dose and
solubility are normally expressed in units of
anhydrous aciclovir.20,42 A stable anhydrous form
can be obtained by drying hydrated aciclovir at
temperatures above 1508C.41 Although only slight
and insignificant differences in solubility values
exist between these two forms, the anhydrous
form of aciclovir possesses poorer dissolution
properties than the hydrated form.41DOI 10.1002/jps JOURNASolubility
Aciclovir is described as ‘‘slightly soluble in water’’
in different Pharmacopoeias.20,21 Most data found
in literature are calculated at room temperature
(22–258C), reporting solubility values that range
from 1.2 to 1.6 mg/mL.41,43–47 In water at 378C,
solubility has been reported to be 2.5 mg/mL.24 A
plot of the pH-solubility in de-ionized water at
378C was published, showing the solubility to vary
slightly with pH, with a lowest solubility of 2.3 mg/
mL at pH 5.8 at 378C.48 The solubility data in
Table 1 were obtained from this pH-solubility
profile.
Partition Coefficient
The partition coefficient (log P) in n-octanol at
228C is 1.57.45,49
At 258C, log P and log D were both reported to be
1.844,50 at pH 6.8. Calculations by Kasim et al.
using fragmentation methods based on atomic
contributions to lipophilicity and by using the
C log P1 program (version 3.0, Biobyte Corp.,
Claremont, CA, http://www.biobyte.com) gave
values of 2.42 for C log P1, and 1.59 for log P,
respectively.51
pKa
Aciclovir is an ampholyte with both weak acid and
basic groups. Common literature pKa values for
aciclovir are 2.27 and 9.25, but it is not stated at
which temperature they were measured.23,24
Balon et al.50 reported pKa values of 2.16 and
9.04 at 378C.L OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 2008
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The WHO Model List of Essential Medicines lists
a dosage strength of 200 mg for aciclovir.19 Most
European countries have Marketing Authoriza-
tions (MAs) for IR solid oral dosage forms of
200 and 400 mg, but some countries also have an
MA for a 800 mg strength, see Table 2. The USA
has MA’s for IR solid oral dosage forms of 200, 400,
and 800 mg.52PHARMACOKINETIC PROPERTIES
Permeability and Absorption
Data found in the literature for Caco-2 perme-
ability are summarized in Table 3.
A permeability study employing 3H-aciclovir
indicated an apparent permeability coefficient of
about 1.19 105 cm/s,53 but other reports
obtained considerably lower values, ranging from
of 0.12 106 44 to 2.0 106 cm/s,54 see Table 3.
As drugs with a permeability in the range 70–
100% absorbed usually have a Papp value greater
than 10 106 cm/s,54 most of these data suggest
that permeability of aciclovir is low. It has also
been hypothesized that a log P value greater than
that of metoprolol (1.72) indicates high perme-
ability.51 As all log P values reported for aciclovir
lie far below that value (see above), according to
this paradigm aciclovir is expected to have low
permeability.
Aciclovir’s absolute BA following oral adminis-
tration has been reported to be in a range of 10–
30% in humans.18,22,23,25 This poor systemic BA is
considered to be a result of the characteristics of
the drug itself and not its delivery vehicle.18,25 Its
absorption occurs mainly by passive diffusion
mechanism and it is slow, variable and incom-
plete.23,55 Maximum plasma concentrations are
reached within 1.5–2.5 h.18,22,23,55,56 Aciclovir
shows a two compartment pharmacokinetic beha-
vior, regardless of the dosage, duration of treat-
ment or frequency of administration.36 After
multiple dose administration, steady-state con-
centrations are reached in 1–2 days.18 Some
studies suggest that increasing doses result in
decreasing BA23,25,35 or less than proportional
increases in Cmax
57and it has been suggested that
this behavior may be due to a saturable carrier
system or a limited area for absorption in the
gastro-intestinal (GI) tract or to the low solubility
of this API.18,46,55 Other studies found near-JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200proportional increases in AUC with increasing
doses in the dose range used clinically of 100–
800 mg.34,47 Food does not appear to affect the rate
and extent of absorption.18,23,25,55Distribution
Aciclovir is widely distributed into most body
tissues, including the brain, kidney, lung, liver,
heart tissue, muscle, spleen, placenta, uterus,
vaginal mucosa and secretions, semen, saliva,
amniotic fluid, aqueous humor and cerebrospinal
fluid.18,23 Aciclovir demonstrates minimal
protein binding (9–33%) at therapeutic plasma
concentrations.18,23,24Metabolism and Excretion
Most of a single aciclovir dose (62–91% of an
intravenous dose) is excreted unchanged in urine
via glomerular filtration and tubular secretion, in
adults with normal renal function.23,24Aciclovir is
metabolized in the liver, partially to 9-(carboxy-
methoxy)methyl]guanine (CMMG) and mini-
mally to 8-[(hydroxy-9-(2-hydroxiethoxy)methyl]-
guanine.18,23,24 The only known urinary metabolite
is CMMG. Plasma concentrations of aciclovir
appear to decline in a biphasic manner. In adults
with normal renal function, t1/2a averages 0.34 h
and t1/2b averages 2.1–3.5 h.
18,23,24,55DOSAGE FORM PERFORMANCE
Bioequivalence of Different Formulations
Six in vivo BE studies comparing drug products
with the innovator drug product, Zovirax1, were
identified. Details of these studies are presented
in Table 4. In all of them, the comparator and the
generic formulations were bioequivalent.58–62
Moreover, in some Summary of Products
Characteristics (SmPCs) of drug products with a
MA in DE, results of successful in vivo BE studies
are reported. The SmPCs of Aciclovir-CT 200/400/
800 mg Tabletten63 reports in vivo BE studies of
each of the three tablet strengths, while the SmPC
of Virzin 200/400/800 mg63 reports in vivo BE
studies of the 400 and 800 mg strength. All these
studies used 20 volunteers and BE was estab-
lished according to AUC, Cmax, and Tmax. It is very8 DOI 10.1002/jps
Table 2. Excipients Present in Aciclovir IR Solid Oral Drug Productsy with a Marketing Authorization (MA) in
Germany (DE), Denmark (DK), Finland (FI), France (FR), The Netherlands (NL), Norway (NO), Spain (ES) and
Sweden (SE),z and the Minimal and Maximal Amount of that Excipient Present Pro Dosage Unit in Solid Oral Drug
Products with a MA in the USA§
Excipient
Drug Products Containing that Excipient
with a MA Granted by the Named Country
Range Present in
Solid Oral Dosage Forms




Cellulose DE(1–16), DK(17–23), ES(24–37), FI(38–47), FR
(48–64), NL(65–73), NO(74–79), SE (80–87)
4.6–1385b
Crospovidone DE(3,6–14,16), DK(18–20), ES(24), FI(39,41,43)
NL(69), NO(76), SE (82,83)
86–500
Croscarmellose ES(27)
Gelatin SE (85) 1–756b
Hypromellose DE(1,2), FI(44,45), NO(77), SE (80) 0.8–86





Magnesium stearate DE(1–16), DK(17–23), ES(24–37), FI(38–47), FR(48–64),
NL(65–73), NO(74–79), SE (80–84,86,87)
0.15–401b
Povidone DE(1,2,4,5,15), DK(21–23), ES(25–37), FI(38,42,46,47),








DE(1–16), DK(17–23), ES(24–26,28–37), FI(38–47),





Starch DE(15), SE (85) 0.44–1135b
Starch, pregelatinized DK(17), FI(40), NL(73), NO(74), SE (81) 6.6–600
1. Zovirax1 200 mg/400 mg/800 mg Filmtabletten (Mono)
2. Acyclovir-ratiopharm1 200 mg/400 mg/800 Filmtabletten (Mono)
3. ACERPES1 800 mg Tabletten (Mono)
4. Acic1 200 Tabletten (Mono)
5. Acic1 400 mg/800 mg Tabletten (Mono)
6. Aciclobeta1 200 Tabletten (Mono)
7. Aciclobeta1 400 mg/800 mg Tabletten (Mono)
8. Aciclostad1 200 mg/400 mg/800 mg Tabletten (Mono)
9. Acyclovir 200 mg/400 mg—1 A Pharma1 Tabletten (Mono)
10. Acyclovir 800—1 A Pharma1 Tabletten (Mono)
11. Acyclovir AL 200 mg/400 mg/800 mg Tabletten (Mono)
12. Acyclovir-CT 200 mg Tabletten (Mono)
13. Acyclovir-CT 400 mg/800 mg Tabletten (Mono)
14. Herpetad1 200 mg Tabletten (Mono)
15. Virzin 200 mg/400 mg Tabletten (Mono)
16. Virzin 800 Tabletten (Mono)
17. Acyclovir Ranbaxy, tabletter 200 mg/400 mg/800 mg
18. Acyclovir 1A Farma, tabletter 200 mg/400 mg/800 mg
19. Acyclovir HEXAL, tabletter 200 mg/400 mg/800 mg
20. Aciclodan, tabletter 200 mg/400 mg/800 mg
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21. Zovir, tabletter 200 mg
22. Zovir, tabletter 400 mg/800 mg
23. Acyclovir Actavis, tabletter 200 mg/400 mg/800 mg
24. Aciclostad1 200/800, comprimidos de 200 mg/800 mg
25. ACICLOVIR BEXAL 200 mg Comprimidos EFG
26. ACICLOVIR BEXAL 800 mg Comprimidos EFG
27. ACICLOVIR COMBINO PHARM 800 mg EFG
28. ACICLOVIR CUVEFARMA 200 mg comprimidos EFG
29. ACICLOVIR CUVEFARMA 800 mg comprimidos EFG
30. ACICLOVIR KORHISPANA 200 mg comprimidos EFG
31. ACICLOVIR KORHISPANA 800 mg comprimidos EFG
32. ACICLOVIR MERCK 200 mg comprimidos EFG
33. ACICLOVIR MERCK 800 mg comprimidos EFG
34. ACICLOVIR RANBAXY 200 mg COMPRIMIDOS EFG
35. ACICLOVIR RANBAXY 800 mg COMPRIMIDOS EFG
36. ACICLOVIR STADA 200 mg COMPRIMIDOS EFG
37. ACICLOVIR STADA 800 mg COMPRIMIDOS EFG
38. Acyclovir Alpharma 200 mg/400 mg/800 mg tabletti
39. Acyclovir HEXAL 200 mg/400 mg/800 mg tabletti
40. Acyclovir Ranbaxy 200 mg/400 mg/800 mg tabletti
41. Aclovir 200 mg/400 mg tabletti
42. Aclovir 800 mg tabletti
43. Acyclostad 200 mg/400 mg/800 mg tabletti
44. ACYRAX 200 mg/400 mg/800 mg tabletti
45. Asikloviiri Orion 200 mg/400 mg/800 mg tabletti
46. Zovirax 200 mg tabletti
47. Zovirax 400 mg/800 mg tabletti
48. ACYCLOVIR ALMUS 200 mg cp
49. ACYCLOVIR ARROW 200 mg/800 mg cp
50. ACYCLOVIR BIOGARAN 200 mg cp
51. ACYCLOVIR BIOGARAN 800 mg cp
52. ACYCLOVIR EG 200 mg/800 mg cp
53. ACYCLOVIR G GAM 200 mg cp
54. ACYCLOVIR MERCK 200 mg cp
55. ACYCLOVIR MERCK 800 mg cp
56. ACYCLOVIR QUALIMED 200 mg/800 mg cp
57. ACYCLOVIR RATIOPHARM 200 mg/800 mg cp
58. ACYCLOVIR RPG 200 mg cp
59. ACYCLOVIR RPG 800 mg cp
60. ACYCLOVIR SANDOZ 200 mg cp
61. ACYCLOVIR SANDOZ 800 mg cp
62. ACYCLOVIR TEVA 200 mg/800 mg cp
63. ZOVIRAX 200 mg cp
64. ZOVIRAX 800 mg cp
65. Acyclovir 200/400/800, tabletten 200/400/800 mg
66. Acyclovir CF 200 mg/400 mg/800 mg, tabletten
67. Acyclovir 200 mg/400 mg/800 mg, tabletten
68. Acyclovir ratiopharm 200 mg/400 mg/800 mg, tabletten
69. Acyclovir Sandoz tablet 200/400/800, tabletten 200/400/800 mg
70. Acyclovir 200/400/800 PCH, tabletten 200/400/800 mg
71. Acyclovir 200 mg, tabletten
72. Acyclovir 400 mg, tabletten
73. Acyclovir 200 mg/400 mg/800 mg, tabletten
74. Acyclovir tabletter Ranbaxy 200 mg/400 mg/800 mg
75. Acyclovir Alpharma 200 mg/400 mg/800 mg tabletter
(Continued)
Table 2. (Continued)
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Table 2. (Continued)
76. Acyclovir HEXAL 200 mg/400 mg/800 mg tabletter
77. Aciklovir Merck NM 200 mg/400 mg/800 mg tabletter
78. Zovirax tabletter 200 mg
79. Zovirax tabletter 400 mg/800 mg
80. Acyclovir Merck NM 200 mg/400 mg/800 mg tabletter
81. Acyclovir Ranbaxy 200 mg/400 mg/800 mg
82. Acyclovir Sandoz 200 mg/400 mg/800 mg, tabletter
83. Aciklovir STADA 200 mg/400 mg/800 mg tabletter
84. Acyclovir Alpharma 200 mg/400 mg/800 mg tabletter
85. Geavir 200 mg/400 mg/800 mg tabletter
86. Zovirax 200 mg tabletter
87. Zovirax 400 mg/800 mg tabletter
Colourants and water are not included.
yExcluded are: dispersible tablets, oral suspension, and oral solutions.
zDE: www.rote-liste.de (assessed February 28, 2007); DK: www.dkma.dk (assessed February 28, 2007); FI: www.nam.fi (assessed
February 28, 2007); FR: www.vidal.fr (assessed February 28, 2007); NL: www.cbg-meb.nl. (assessed February 27, 2007); NO:
www.legemiddelverket.no (assessed March 1, 2007); ES: www.agemed.es (assessed February 28, 2007); SE: www. lakemedelsver-
ket.se (assessed March 1, 2007).
§USA: http://www.fda.gov/cder/iig/iigfaqweb.htm#purpose (version date January 9, 2007).
aIncludes aluminum magnesium silicate and aluminum magnesium trisilicate.
bThe upper range value reported is unusual high for solid oral dosage forms and the authors doubt on its correctness.
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In the above-mentioned BE studies, various
excipients were used in the formulations.
Aciclovir-CT tabletten contain cellulose, crospo-
vidone, magensium stearate, sodium starch gly-
colate, lactose (200 and 400 mg strengths only)
and silica (800 mg strength only);63 Virzin
contains cellulose; magnesium stearate silica,
sodium starch glycolate, starch (200 and 400 mg
strengths only), crospovidone (800 mg strength
only) and povidone (200 and 400 mg strengths
only),63 whereas Zovirax1 contains aluminum
magnesium silicate, cellulose, hypromellose,
macrogol, magnesium stearate, povidone, and
sodium starch glycolate;63 see also Table 2.
A study carried out with Caco-2 showed that, of
nine common excipients studied, only sodium
lauryl sulfate slightly increased the permeabilityTable 3. Apparent Permeability of Aciclovir in Caco-2 Cel
Permeability







11.9 7 0.5 mCi/
(A), apical compartment; (B), basolateral compartment.
DOI 10.1002/jps JOURNAof aciclovir, whereas lactose, hydroxypropyl
methyl cellulose, Tween 80, propylene glycol,
polyethylene glycol 400, dioctyl sodium sulfosuc-
cinate, sodium EDTA and anhydrous cherry
flavor, had no effect on the permeability.64
Excipients present in aciclovir IR solid oral drug
products with a MA in Germany (DE), Denmark
(DK), Finland (FI), France (FR), The Netherlands
(NL), Norway (NO), Spain (ES) and Sweden (SE),
are shown in Table 2. Additionally, the minimum
and maximum amount of the listed excipients
present per dosage unit in solid oral drug products
with a MA in the USA, taken from the FDA
Inactive Ingredient Data Base,65 is indicated.
It can be expected that the drug products having
a MA in the reported countries successfully passed
an in vivo BE study. In DE, the exemption from
demonstration of BE in vivo that existed for some
APIs in the 1980s and 1990s was not applied tol Monolayers
ial Concentration References
mM (not specified) Bergstrom et al.44
1 mM (not specified) Yazdanian et al.74
Not specified Friedrichsen et al.75
Not specified de Vrueh et al.76
elow saturation Rege et al.64
Not specified Yee54
mL (radioactive ACV) Salama et al.50
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Table 4. Aciclovir Bioequivalence Studies Found in Literature
Reference
Composition of















Rojanasthien 200 mg tablet Two-period Not reported T1/2 Test formulation
et al.60 crossover Tmax bioequivalent
AUC0–1
Cmax
Vergin et al. 58; 200 mg tabletþ Three-way 24 Cmax Test formulation













5068 ARNAL ET AL.aciclovir.66 Similarly, aciclovir is not on the list of
APIs exempted from demonstration of BE in vivo
for IR solid oral drug products seeking a national
MA only in The Netherlands.67Dissolution
The USP 29 dissolution specifications for Aciclovir
Tablets are not less than 80% (Q) of the labeled
amount dissolved within 45 min in 900 mL of 0.1 N
hydrochloric acid, using the paddle at 50 rpm, and
for Aciclovir Capsules the specification is not less
than 75% (Q) within 45 min in 900 mL of 0.1 N
hydrochloric acid, using the basket at 100 rpm,
respectively.20 The dissolution of the innovator
and five generic drug products, each containing
800 mg aciclovir, was compared using USP
apparatus 2 and USP apparatus 3. The dissolution
of all drug products was complete within in
15 min, in both apparatus.68
One of the six in vivo BE studies mentioned
above compared the dissolution of innovator andJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 200generic drug products as stipulated by USP XXIII,
finding them to be not statistically different.61DISCUSSION
Solubility
D/S values for different pHs are shown in Table 1.
The WHO recommended dosage strength and the
400 mg strength qualify as highly soluble accord-
ing to all Guidelines.2–4 However, in some
markets, the highest dosage strength is 800 mg,
for which that criterion is not met.Permeability
The BA for aciclovir ranges from 10% to 30%,
indicating, given the small amount of metabolism,
that this API is not highly permeable according to
all Guidelines.2–4 Caco-2 permeability data and
log Poct values support that conclusion.8 DOI 10.1002/jps
BIOWAIVER MONOGRAPH FOR ACICLOVIR 5069BCS Classification
Combining the data on solubility and perme-
ability, according to all Guidelines,2–4 the 200 and
400 mg tablet strengths are BCS Class III. Kasim
et al.51 also classified aciclovir as BCS Class III,
but their classification was based on correlations
of partition coefficients with permeability, a
method not supported by HHS-FDA and other
regulatory authorities due to its limited predict-
ability. Lindenberg et al.69 and the recently
adopted revised WHO Guideline 2 also classify
aciclovir as BCS Class III. Wu and Benet,70 using
the disposition characteristics of the API as
estimate for its permeability, assigned aciclovir
to Class III of their Biopharmaceutics Drug
Disposition Classification System (BDDCS). For
pH values 4.5 and above, the 800 mg tablet
strength shows D/S ratio’s outside the 250 mL
limit. If 800 mg is taken as highest tablet strength,
aciclovir would be classified in BCS Class IV.Surrogate Techniques for In Vivo
Bioequivalence Testing
The low permeability of aciclovir is the limiting
step in its absorption process. Bioinequivalence
caused by differences in GI permeability between
test and comparator, caused by an excipient effect,
can only be circumvented by formulating the test
product only with excipients known not to
affect GI permeability. Bioinequivalence caused
by differences in in vivo disintegration and/or
in vivo dissolution between test and comparator,
being a potential cause of bioinequivalence in
particular for 800 mg tablet strengths, can be
excluded by requiring the comparator and the test
product to be both very rapidly dissolving, that is,
dissolve 85% in 15 min or less, using a basket
apparatus at 100 rpm or paddle apparatus at
50 rpm, in a volume of 900 mL or less, in the three
BCS-media.2,71–73Risks of Excipient and/or Manufacturing to
Cause Bioinequivalence
One report was identified of an excipient interac-
tion, being an in vitro study only, using Caco-2,
with sodium laurylsulfate, and the effect was
limited.64 For the excipients shown in Table 2, it
can be supposed that they show no influence
on the absorption of aciclovir when present in
usual amounts; note that Table 2 does not includeDOI 10.1002/jps JOURNAsodium laurylsulfate. From a more general
perspective, aciclovir seems not to be a critical
API with respect to a risk for bioinequivalence: not
one single example of bioinequivalence was
identified, whereas eight in vivo BE studies were
identified demonstrating in vivo BE of different
formulations. Furthermore, 87 drug products
(with MAs) were identified, for which it can be
assumed that an in vivo BE study was successfully
passed, which contain a wide variety of composi-
tions with respect to excipients.Patient’s Risks Associated with Bioinequivalence
Aciclovir has a broad therapeutic index.
Oral administration of aciclovir is usually well
tolerated, and oral overdosing does not provoke
serious adverse effects. Oral aciclovir has no life-
threatening indication, and its therapeutic range
seems wide enough to open the possibility for a
biowaiver.CONCLUSION
Aciclovir cannot unequivocally be classified to the
BCS because different countries have different
highest tablet strengths on their markets, which
would lead to different BCS classifications in
different countries. But the BCS classification of
an API is not a purpose in itself, the relevant
question being: is a biowaiver scientifically
justified and if justified, which restrictions have
to be formulated?
Up to now, the FDA3 and the EMEA4 do not
accept biowaivers for BCS Class III and BCS
Class IV APIs, so acyclovir would obviously be
excluded from consideration for a biowaiver in
these jurisdictions at the present time. However,
the recently revised WHO guidance2 extended
the possibility of a biowaiver approval to BCS
Class III APIs under certain conditions.
The risk of an acyclovir drug product being
bioinequivalent appears to be very low, provided it
contains only excipients present in IR aciclovir
solid oral drug products approved in ICH or
associated countries, for instance those presented
in Table 2 of this article, and meets the biowaiver
dissolution criteria. Also, the patient risks asso-
ciated with a bioinequivalence inadvertently not
detected by application of in vitro BE test can be
deemed acceptable.L OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 12, DECEMBER 2008
5070 ARNAL ET AL.The preponderance of evidence indicates that a
biowaiver for IR aciclovir solid oral drug products
with strengths up to 800 mg is justified, if: (a) the
test product contains only excipients present in
aciclovir solid oral drug products approved in ICH
or associated countries, for instance as presented
in Table 2 of this article, and (b) the comparator
and the test product both are very rapidly
dissolving, that is, dissolve 85% in 15 min
or less, using a basket apparatus at 100 rpm or
paddle apparatus at 50 rpm, in a volume of 900 mL
or less, in pH 1.2, pH 4.5, and pH 6.8 buffers.ACKNOWLEDGMENTS
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